​

We are delighted to share the findings, recently published in The Lancet, from the first-in-human study by Dr Andrew Dean, Chair of WARPNINE, and colleagues.

​

Although early phase, this study showed the best ever result ever seen in a pancreatic cancer trial.

This article was published in The Lancet Gastroenterology & Hepatology, Vol 7, Andrew Dean, Sanjeev Gill, Mark McGregor, Vy Broadbridge, Harri A Järveläinen, Timothy Price, Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study, Copyright Elsevier Ltd (2022).